ESC 2019: Circulating Dipeptidyl Peptidase-3 - Prof Alexandre Mebazaa
What's new in 2019 ESC Guidelines for Diabetes, Pre-diabetes and Cardiovascular diseases
21 Inotropes Alexandre Mebazaa (H_dyn2017)
ISISCEM20, Sepsis, Adrecizumab in patients with high adrenomedullin levels, Pierre–François Laterre
DPP3 : facteur circulant dépresseur du myocarde lors du choc cardiogénique - ESC Congress 2019
Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin...
Darren K. McGuire | Antihyperglycemic Medications for Cardiovascular Risk Reduction
What's new in 2019 ESC gudielines for DM&CVD - Dr. Ahmed Mohsen
Professor Milton Packer - 'Heart failure – are there limits to anti-diabetic therapy with SGLT2'
Covid 19 : Pour renforcer les équipes de réa, les soignants venus de l'extérieur sont formés
Sevrage ventilatoire difficile M. DRES #REANIMATION2019
Diabetes and the Heart. ESC Guidelines: Part 2
Emory Cardiology Grand Rounds 02-24-2020
What is Peptidase
Darren McGuire | Cardiovascular effects of diabetes medications: Lessons learned from CVOTs
Evidence- based Approach in selecting ideal partner with Metformin | Dr. Nilanjan Sengupta.
Deepak L. Bhatt | Residual CV Risk in Statin-Treated Patients with Elevated Triglycerides
Medicine Grand Rounds: Diabetes and Cardiovascular Disease 3/26/19
New diabetes treatments and the role of the laboratory
Mercodia Webinar: Dr. Ralph DeFronzo: Glucagon Release with SGLT2 Inhibition
